Identification of natural small molecule modulators of MurB from Salmonella enterica serovar Typhi Ty2 strain using computational and biophysical approaches
Proteins: Structure, Function, and Bioinformatics · 2023-03 · 91 (3) · 363-379
DOI: 10.1002/prot.26435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteins: Structure, Function, and Bioinformatics, online erschienen am 18.10.2022. Verfasst von Md Anzarul Haque und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Salmonella typhi, Berberine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
The increase of antibiotic‐resistant bacterial pathogens has created challenges in treatment and warranted the design of antibiotics against comparatively less exploited targets. The peptidoglycan (PG) biosynthesis delineates unique pathways for the design and development of a novel class of drugs. Mur ligases are an essential component of bacterial cell wall synthesis that play a pivotal role in PG biosynthesis to maintain internal osmotic pressure and cell shape. Inhibition of these enzymes can interrupt bacterial replication and hence, form attractive targets for drug discovery. In the present work, we focused on the PG biosynthesis pathway enzyme, UDP‐ N ‐acetylpyruvylglucosamine reductase, from Salmonella enterica serovar Typhi (stMurB). Biophysical characterization of purified StMurB was performed to gauge the molecular interactions and estimate thermodynamic stability for determination of attributes for possible therapeutic intervention. The thermal melting profile of MurB was monitored by circular dichroism and validated through differential scanning calorimetry experiment. Frequently used chemical denaturants, GdmCl and urea, were employed to study the chemical‐induced denaturation of stMurB. In the search for natural compound‐based inhibitors, against this important drug target, an in silico virtual screening based investigation was conducted with modeled stMurB structure. The three top hits (quercetin, berberine, and scopoletin) returned were validated for complex stability through molecular dynamics simulation. Further, fluorescence binding studies were undertaken for the selected natural compounds with stMurB alone and with NADPH bound form. The compounds scopoletin and berberine, displayed lesser binding to stMurB whereas quercetin exhibited stronger binding affinity than NADPH. This study suggests that quercetin can be evolved as an inhibitor of stMurB enzyme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Md Anzarul Haque, Punit Kaur
Förderung
- Indian Council of Medical Research
Zitieren
APA
Haque, M. A., Singh, M., Tripathi, M. K., Ethayathulla, A. S., & Kaur, P. (2023). Identification of natural small molecule modulators of MurB from Salmonella enterica serovar Typhi Ty2 strain using computational and biophysical approaches. Proteins: Structure, Function, and Bioinformatics, 91(3), 363-379. https://doi.org/10.1002/prot.26435
Vancouver
Haque MA, Singh M, Tripathi MK, Ethayathulla AS, Kaur P. Identification of natural small molecule modulators of MurB from Salmonella enterica serovar Typhi Ty2 strain using computational and biophysical approaches. Proteins: Structure, Function, and Bioinformatics. 2023;91(3):363-379. doi:10.1002/prot.26435
BibTeX
@article{Haque2023,
author = {Haque, Md Anzarul and Singh, Mandeep and Tripathi, Manish Kumar and Ethayathulla, Abdul Samath and Kaur, Punit},
title = {Identification of natural small molecule modulators of MurB from Salmonella enterica serovar Typhi Ty2 strain using computational and biophysical approaches},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2023},
volume = {91},
number = {3},
pages = {363--379},
doi = {10.1002/prot.26435}
}
EUVIMED